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Abstract
Proteoglycan and glycosaminoglycan content was analyzed in a model
of rat mammary carcinoma to study the roles of these compounds in
tumorigenesis. Hyaluronic acid and proteoglycans bearing chondroitin
and/or dermatan sulfate chains were detected in solid tumors obtained
after subcutaneous inoculation of Walker 256 rat carcinoma cells.
About 10% of sulfated glycosaminoglycan chains corresponded to
heparan sulfate. The small leucine-rich proteoglycan, decorin, was
identified as one of the proteoglycans, in addition to others of higher
molecular weight, by cross-reaction with an antiserum raised against
pig laryngeal decorin and by N-terminal amino acid sequencing.
Decorin was separated from other proteoglycans by hydrophobic
chromatography and its complete structure was determined. It has a
molecular weight of about 85 kDa and a dermatan chain of 45 kDa
with 4-sulfated disaccharides. After degradation of the glycosami-
noglycan chain, three core proteins of different molecular weight (36,
46 and 56 kDa) were identified. The presence of hyaluronic acid and
decorin has been reported in a variety of tumors and tumor cells. In the
Walker 256 mammary carcinoma model, hyaluronic acid may play an
important role in tumor progression, since it provides a more hydrated
extracellular matrix. On the other hand, decorin, which is expressed by
stromal cells, represents a host defense response to tumor growth.
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Introduction
Proteoglycans are complex macromol-
ecules composed of a protein core to which
at least one glycosaminoglycan chain is co-
valently linked. They are ubiquitous mol-
ecules and may be localized inside the cells,
on the cell surface, or within the extracellular
matrix. Proteoglycans also have a variety of
functions in physiological and pathological
conditions.
During tumor development, many alter-
ations may occur in the composition of pro-
teoglycans in the tissue. The main alteration
is an increase in chondroitin sulfate (CS)
content (1). Many different proteoglycans
bearing CS chains have been described, such
as the basal membrane proteoglycan perlecan
(2), the high molecular weight proteoglycan
versican/PG-M (3,4) and the small extracel-
lular proteoglycan decorin (5), amongst oth-
ers.
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Decorin is a key regulator of extracellu-
lar matrix assembly and is a member of the
small leucine-rich proteoglycan family (6).
There is an increasing amount of evidence
suggesting an important role of decorin in
cell proliferation. Overexpression of deco-
rin leads to growth inhibition in a variety of
cell types (7,8). Decorin may also play an
important role in tumorigenesis, since not
only does decorin expression decrease in
various tumor cell types (9), but secretion of
decorin by peritumoral stroma of colon can-
cer is also increased (10). This may repre-
sent a defense mechanism of the tumor stroma
designed to counterbalance the invasive tu-
mor cells.
Walker 256 is a rat cell lineage of mam-
mary carcinoma discovered and isolated by
George Walker in 1928 (11). Fiszer-Szafars
and Giullino (12) observed the presence of
hyaluronic acid (HA) in the interstitial fluid
of this tumor. This in vivo animal model of
neoplastic development, the Walker 256
mammary carcinoma, was used in the pres-
ent study to analyze the compositions of
glycosaminoglycan and proteoglycan. We
confirmed that HA is present in this tumor
and demonstrated that the small proteogly-
can decorin is one of the proteoglycan ex-
pressed. Both HA and decorin are probably
synthesized by stromal cells trying to defend
the host against tumor cell growth.
Material and Methods
Materials
Guanidine hydrochlorate (GuaHCl), ben-
zamidine HCl, α-aminocaproic acid, iodo-
acetamide, phenylmethylsulfonyl fluoride,
HA (bovine trachea), chondroitinase ABC
(Proteus vulgaris), deoxyribonuclease
(DNase) I, and DEAE-cellulose were from
Sigma (St. Louis, MO, USA). Anti-rabbit
IgG, biotinylated whole goat streptavidin
horseradish-peroxidase, Sepharose CL-4B
and Octyl-Sepharose CL-4B were purchased
from Amersham Biosciences (Uppsala, Swe-
den). Chondroitinase AC II (Arthrobacter
aurenses) and standard glycosaminoglycans
(chondroitin 4-sulfate, chondroitin 6-sulfate
and dermatan sulfate, DS) were from
Seikagaku Kogyo Co. (Tokyo, Japan). Hep-
aran sulfate (HS) was prepared as described
previously (13). The polyclonal antibody
used was raised against pig laryngeal carti-
lage decorin (14). Tumoral cells of the Walker
256 strain or rat mammary carcinoma were a
gift from Dr. Ovideo Rettori, Universidade
Estadual de Campinas, Campinas, SP, Bra-
zil. White male 3- to 5-month-old Sprague-
Dawley rats were used for all the experi-
ments.
Tumors
Tumor cells were grown in the ascitic
and solid forms. Ascitic tumor was obtained
by intraperitoneal inoculation of 40 million
cells diluted in PBS. After 4 days, cells were
removed from the peritoneal cavity by aspi-
ration of ascitic fluid and diluted in PBS, and
the number of neoplastic cells was deter-
mined.
Solid tumor was obtained by four subcu-
taneous inoculations of 4 million tumor cells
into the dorsal region of male rats. After 7
days, animals bearing tumors were sacri-
ficed and tumors were removed. Metabolic
radiolabeling of tumors was performed by
intraperitoneal injections of 2 mCi [35S]-
sulfate (IPEN, São Paulo, SP, Brazil), 6 h
before sacrifice.
Isolation of glycosaminoglycans
Tumors were ground with 10 volumes of
acetone and after standing overnight at
-20ºC the mixture was centrifuged. One gram
of the dried precipitate was then resuspended
in 10 ml of 50 mM Tris-HCl buffer, pH 8.0,
containing 0.15 M NaCl and 2 mg/ml
maxatase (Biocon, Rio de Janeiro, RJ, Bra-
zil). The mixture was incubated overnight at
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50ºC and centrifuged. NaCl and trichloro-
acetic acid were added to the supernatant up
to 1 M and 10% of the final concentration,
respectively, and the precipitate which
formed was removed by centrifugation. Gly-
cosaminoglycans in the supernatant were
precipitated with 2 volumes of ethanol
(-20ºC, 24 h). The ethanol precipitate col-
lected by centrifugation was dried and incu-
bated with DNase I in 50 mM sodium ace-
tate, pH 6.0, for 18 h at 37ºC. Qualitative and
quantitative analyses of glycosaminoglycans
were performed by agarose gel electropho-
resis.
Isolation of proteoglycans
Proteoglycans were extracted from diced
solid tumor tissue in a dissociative solution
containing 4 M GuaHCl in 50 mM sodium
acetate, pH 6.0, proteinase inhibitors (100
mM α-aminocaproic acid, 6.5 mM benzami-
dine HCl, 5.5 mM iodoacetamide, and 0.1
mM phenylmethylsulfonyl fluoride, 5 ml/g
of tissue). The homogenate was centrifuged
and the precipitation step was repeated. Both
supernatant solutions were precipitated with
2 volumes of ethanol. The supernatant was
removed by centrifugation and excess etha-
nol was evaporated to dryness. The ethanol
precipitates were re-dissolved in 6 M urea
buffered with 25 mM Tris-HCl, pH 6.8, and
ultracentrifuged (100,000 g, 30 min, 4ºC)
before being submitted to ion-exchange chro-
matography on DEAE-cellulose.
Ion-exchange chromatography
The solution containing proteoglycans in
6 M urea buffered with 25 mM Tris-HCl, pH
6.8, added to DEAE-cellulose (0.1 ml/g wet
tissue) was submitted to gentle shaking. Af-
ter 12 h at 4ºC the resin was packed into a
glass chromatography column and washed
with 30 volumes of 6 M urea. Elution was
performed in Tris-buffered urea containing
0.2 M NaCl (30 volumes) and 2 M NaCl
(5 volumes). Proteoglycans (radioactivity)
were eluted with the second eluate and then
dialyzed against distilled water and lyo-
philized.
Hydrophobic interaction chromatography
Materials eluted with 2 M NaCl from
DEAE-cellulose were added to Octyl-Sepha-
rose CL-4B (0.5 ml/g wet tissue), previously
equilibrated with 0.15 M sodium acetate, pH
6.3, containing 1 M GuaHCl, for 12 h at 4ºC.
Resin was packed in a glass chromatography
column and washed with 5 volumes of 0.15
M sodium acetate, pH 6.3, containing 1 M
GuaHCl (fraction Oc-1M) and eluted with 5
volumes of 0.15 M sodium acetate, pH 6.3,
containing 6 M GuaHCl (fraction Oc-6M).
Both Oc-1M and Oc-6M were dialyzed ex-
haustively against distilled water, lyophilized
and resuspended in 50 mM sodium acetate,
pH 5.8, containing 4 M GuaHCl.
Size-exclusion chromatography
Fractions obtained by Octyl-Sepharose
chromatography, Oc-1M and Oc-6M, were
further chromatographed separately on
Sepharose CL-4B columns (112 x 1.5 cm)
equilibrated and eluted with 4 M GuaHCl
and 50 mM sodium acetate, pH 5.8, at a flow
rate of 0.5 ml/min. The effluent collected (2
ml) was monitored at 280 nm and an aliquot
was used to determine the amount of radio-
activity. Fractions containing proteoglycans
were pooled, dialyzed against distilled wa-
ter, and lyophilized.
Agarose gel electrophoresis
Proteoglycans and glycosaminoglycans
were identified and quantified by agarose
gel electrophoresis in 50 mM 1,3-diamino-
propane buffer, pH 9.0, by the method of
Dietrich and Dietrich (15). Electrophoresis
was performed for about 1 h at 100 V and
compounds were precipitated in the gel with
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0.1% Cetavlon (N-acetyl-N,N,N-trimethyl-
ammonium bromide) for at least 2 h. The gel
was dried and stained with 0.1% toluidine
blue in 1% acetic acid and 50% ethanol. For
HA visualization, the gel was stained with
0.1% toluidine blue in 25 mM sodium ace-
tate buffer, pH 5.0. Glycosaminoglycan iden-
tification was based on the migration of the
compounds compared to standards. Quanti-
fication was carried out by densitometry at
530 nm, with the error of the method being
about 5%. Gel slices were cut and counted in
scintillation liquid for identification of [35S]-
sulfate-radiolabeled proteoglycan and gly-
cosaminoglycan.
Preparative gel electrophoresis was per-
formed as a last proteoglycan purification
step. Different proteoglycans were separated
according to their differential electrophoret-
ic mobility. Agarose gel was cut and the gel
containing proteoglycans was eluted by cen-
trifugation after freezing and thawing the
agarose gel.
SDS-PAGE
Electrophoresis for protein analysis was
carried out on 6% polyacrylamide gels con-
taining SDS. Protein bands were detected by
silver staining (16), Coomassie blue R-250
staining, or with specific antibodies by im-
munoblotting, while glycosaminoglycan  and
proteoglycan were stained with toluidine
blue.
Immunoblotting
Proteoglycans electrophoresed on aga-
rose gel were transferred to nitrocellulose
sheets by diffusion, while materials on poly-
acrylamide gels were electrotransferred to
nitrocellulose sheets. Decorin antiserum
(anti-pig cartilage decorin) was used at
1:5,000 dilution. Bound antibodies were lo-
calized with a biotin-conjugated second an-
tibody (1:10,000) and peroxidase-conjugated
streptavidin (1:10,000).
Characterization of proteoglycans
Samples of the protein cores were pre-
pared by digesting the proteoglycan (10 µg)
with chondroitinase ABC (0.2 mU/µg pro-
teoglycan) in 100 mM Tris-HCl, 10 mM
sodium fluoride, containing the mixture of
protease inhibitors described earlier at pH
7.3, for 18 h at 37°C.
Relative size and electrophoretic migra-
tion of glycosaminoglycan chains attached
to the proteoglycan were determined after
alkaline ß-elimination (0.5 M NaOH, 1 M
NaBH4, 50°C, 16 h). Solutions were neutral-
ized with acetic acid, dialyzed against dis-
tilled water and lyophilized.
The relative contents of disaccharides of
the glycosaminoglycan chains were deter-
mined by descending paper chromatography
after chondroitinase B, AC and ABC treat-
ment. About 20 µg of proteoglycan were
incubated with 15 mU of enzyme for 18 h in
10 mM Tris-acetate buffer, pH 7.5, at room
temperature (chondroitinase B), or in 50 mM
Tris-acetate buffer, pH 8.0, at 37°C (chon-
droitinase AC and ABC).
The N-terminal amino acid sequence of
the protein core was determined with an
automatic protein and peptide sequencer
(model ABI 476A, Perkin-Elmer, Foster City,
CA, USA).
Analytical procedures
Protein content was determined by the
method of Spector (17) using Coomassie
blue G-250, with bovine serum albumin as
standard.
Results
Glycosaminoglycan contents of Walker 256
tumor
Solid Walker 256 tumor was shown to
contain glycosaminoglycans by agarose gel
electrophoresis. The major sulfated gly-
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cosaminoglycan chains had an intermediate
migration between DS and CS shown by
toluidine blue staining (Figure 1C) and by
[35S]-sulfate-incorporated glycosaminogly-
can (Figure 1B). It corresponded to about
90% of total sulfated glycosaminoglycan in
the tissue (Table 1). The remaining 10%
sulfated glycosaminoglycan corresponded to
HS. Additionally, a large amount of HA was
also observed (Figure 1A,C).
Proteoglycan purification
Proteoglycans were extracted from solid
tumors of Walker 256 rat carcinoma and
subsequently purified for analysis of the pro-
teoglycans that could be bearing CS/DS
chains. Proteoglycans were extracted from
tissue with 4 M GuaHCl and submitted to
DEAE-cellulose chromatography, and then
to Octyl-Sepharose CL-4B chromatography.
Analysis of the hydrophobic fractions by
agarose gel electrophoresis showed separa-
tion of the fraction which interacts with Octyl-
CS/DS
CS
HS
HA
Origin
DS
HS
Origin
WK HA S WK WK HA S
A CB
Table 1. Walker 256 carcinoma sulfated glycosami-
noglycans.
Sulfated Specific activity
glycosaminoglycan (cpm × 103/g
(µg/g dry tissue)  dry tissue)
CS/DS 1069.6 2984.4
HS 132.1 326.4
The amount of each sulfated glycosaminoglycan
(CS/DS, chondroitin sulfate/dermatan sulfate; HS,
heparan sulfate) was determined by densitometry
of the electrophoresis gel stained with toluidine
blue (Figure 1). The total amount of [35S]-sulfate
incorporated into each sulfated glycosaminogly-
can was determined after cutting the gel and
counting in scintillation liquid.
Sepharose, corresponding to about 30% of
total sulfated glycosaminoglycan (Oc-6M).
The other fraction, which did not interact
with Octyl-Sepharose (Oc-1M), was com-
posed of bands with different electrophoret-
ic mobility, possibly representing different
proteoglycans. Fraction Oc-6M showed a
single proteoglycan band, while fraction
Figure 1. Glycosaminoglycan composition of Walker 256 carcinoma. About 10 µg glycosaminoglycan obtained after
Walker 256 carcinoma (WK) proteolysis was applied to an agarose gel slab in 50 mM Tris-acetate buffer, pH 8.0 (A),
or in 50 mM 1,3-propylenediamine-acetate buffer, pH 9.0 (C), and subjected to electrophoresis at 4ºC.
B, Autoradiography of the agarose gel electrophoresis presented in panel A. Glycosaminoglycan chains were
visualized after fixation with Cetavlon, drying and staining with toluidine blue. Quantification was performed by
densitometry and results are reported in Table 1. CS, chondroitin sulfate; DS, dermatan sulfate; HA, hyaluronic
acid; HS, heparan sulfate; S, standard sulfated glycosaminoglycan.
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Oc-1M seemed to consist of a mixture of
proteoglycans, since more than one band
was observed following electrophoretic sepa-
ration on agarose gel (Figure 2). Both frac-
tions were rechromatographed separately on
Sepharose CL-4B columns (Figure 3). The
two fractions have the same kav (0.44), al-
though fraction Oc-1M has a wider elution
profile, indicating that there is more than one
component, as shown previously in Figure 2.
These proteoglycans might have different
molecular weights. A pool of the Oc-6M
fraction was submitted to preparative aga-
rose gel electrophoresis for further charac-
terization.
Characterization of proteoglycan Oc-6M
Fraction proteoglycan Oc-6M was ana-
lyzed before and after alkaline ß-elimination
by agarose (Figure 4A) and polyacrylamide
gel electrophoresis (Figure 4B). Free gly-
cosaminoglycan chains showed intermedi-
ate agarose electrophoretic migration be-
tween CS and DS standards, and a molecular
weight of about 45 kDa. Intact proteoglycan
had an 85-kDa molecular weight and elec-
trophoretic migration similar to that of stan-
dard HS on agarose gel. Yet, this proteogly-
can cross-reacted with an antiserum raised
against pig laryngeal cartilage decorin (Fig-
ure 4C).
Proteoglycan Oc-6M was incubated with
chondroitinase for analysis of glycosami-
noglycan structure and was found to be par-
tially degraded by chondroitinase AC and
totally degraded by chondroitinase ABC (Fig-
ure 5). Only 4-sulfated disaccharides were
present in the structure. After incubation
with chondroitinase B, which degrades only
the ß(1→4) linkage between acid N-acetyl-
D-galactosamine and L-iduronic acid, only
small amounts of 4-sulfated disaccharides
were released. The amount of unsaturated 4-
sulfated disaccharides obtained by the ac-
tion of chondroitinase AC was equal to 50%
of the total disaccharides obtained by the
action of chondroitinase ABC. Since chon-
droitinase AC acts on ß(1→4) linkages be-
tween hexosamine and D-glucuronic acid,
these data indicated the presence of L-
iduronic acid residues in the molecule, per-
mitting us to classify it as a DS. The differ-
ences in electrophoretic migration on aga-
rose gel between CS and DS were due to
their differences in L-iduronic acid and D-
glucuronic acid proportions.
Fraction proteoglycan Oc-6M was incu-
bated with chondroitinase ABC to analyze
the core protein. There were at least three
different sized core proteins with molecular
weights of 56, 46 and 36 kDa detected by
Coomassie blue (Figure 6A) and by immu-
noblotting using anti-decorin antibodies (Fig-
ure 6B).
N-terminal amino acid sequencing of pro-
teoglycan Oc-6M showed a single sequence
(Figure 7). Although it was not possible to
identify residues at positions 17 and 19, this
was confirmed to be decorin because of its
homology with core proteins of mouse deco-
rin and by homology with decorin core pro-
tein of other species.
Discussion
We examined the glycosaminoglycan  and
proteoglycan composition of Walker 256 rat
mammary carcinoma. Besides HA, there were
large amounts of sulfated glycosaminogly-
can. About 90% of total sulfated glycosami-
noglycan corresponded to CS/DS chains, and
the remaining ones to HS. The presence of
HA in Walker 256 rat mammary carcinoma
has been previously described by Fiszer-
Szafars and Giullino (12). In other tumors,
the presence of HA has been correlated with
invasive and metastatic behavior since an
extracellular matrix rich in HA becomes more
hydrated and can support adhesion and loco-
motion of tumoral cells (18).
Our analysis of Walker 256 rat carcino-
ma proteoglycans indicated the production
of different proteoglycans bearing CS and/or
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Figure 2. Densitometric profiles of proteoglycans obtained
from Walker 256 carcinoma before and after Octyl-Sepha-
rose CL-4B chromatography and subjected to agarose gel
electrophoresis. Proteoglycans eluted with 2 M NaCl from
DEAE-cellulose were chromatographed on Octyl-Sepharose
CL-4B. Proteoglycans were divided into two fractions: one
that was eluted with 1 M GuaHCl (Oc-1M), and the other
eluted with 6 M GuaHCl (Oc-6M). Aliquots of each fraction
were subjected to agarose gel electrophoresis (50 mM 1,3-
propylenediamine-acetate buffer, pH 9.0). After fixation, dry-
ing and staining the gel slab was exposed to an X-ray film.
The figure shows the densitometric profiles of autoradiog-
raphy of both fractions separated after Octyl-Sepharose CL-
4B chromatography. CS (chondroitin sulfate), DS (dermatan
sulfate) and HS (heparan sulfate) are standard sulfated gly-
cosaminoglycans.
Figure 3. Sepharose CL-4B elution profiles of proteoglycans
from Walker 256 carcinoma. Fractions Oc-1M and Oc-6M
from Octyl-Sepharose CL-4B were chromatographed on
Sepharose CL-4B, which was equilibrated and eluted with 4
M GuaHCl, 50 mM sodium acetate, pH 5.8. Protein (20 µl)
and sulfated glycosaminoglycans (30 µl) were determined
by absorbance and radioactivity, respectively, in the 2 ml
fractions collected. Fractions containing proteoglycans were
pooled as indicated by the upper horizontal bar in the lower
panel, dialyzed and lyophilized for further purification. V0 =
void volume; Vt = totally included volume.
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Origin Origin
CS
DS
HS
CS
DS
HS
58 kDa
21 kDa
9.9 kDa
4.5 kDa
A B C
Figure 4. Electrophoretic analysis of proteoglycan frac-
tion Oc-6M. A, About 0.5 µg Oc-6M proteoglycan (W)
and control cartilage pig decorin (Dec) was subjected to
agarose gel electrophoresis (50 mM 1,3-diaminopro-
pane buffer, pH 9.0) and transferred to a nitrocellulose
membrane. Immunostaining was performed using de-
corin antiserum and the biotin-streptavidin-peroxidase
complex. B, About 5 µg proteoglycan Oc-6M was sub-
jected to agarose gel electrophoresis (50 mM 1,3-di-
aminopropane buffer, pH 9.0) before (-) and after (+)
alkaline ß-elimination as described in Methods. CS,
chondroitin sulfate; DS, dermatan sulfate; HS, heparan
sulfate; S, standard glycosaminoglycans. C, About 15
µg proteoglycan Oc-6M was subjected to a 6% SDS-
PAGE before (-) and after (+) alkaline ß-elimination. Gel
was fixed with 10% acetic acid and 25% methanol and
stained with toluidine blue. Molecular weight standards
for glycosaminoglycan are: chondroitin 6-sulfate (58
kDa), chondroitin 4-sulfate (21 kDa), heparan sulfate C
(9.9 kDa), and heparan sulfate D (4.5 kDa).
Figure 5. Relative amounts of unsaturated 4-sulfated
disaccharides (∆Di-4S) formed by the action of different
chondroitinases on Oc-6M proteoglycan (PG). About 20
µg purified PG was incubated with chondroitinase B,
AC and ABC in a final volume of 15 µl. The incubation
mixtures were applied to Whatman No. 1 filter paper
and chromatographed in isobutiric acid, 1 M NH4OH
(5:3, v/v). The unsaturated products formed were visu-
alized by UV light and by alkaline silver staining. The
figure shows the relative amounts of degradation cal-
culated by densitometry of unsaturated 4-sulfated di-
saccharide bands after silver staining.
Figure 6. SDS-PAGE and immunoblotting of proteogly-
can (PG) Oc-6M from Walker 256 carcinoma. About 1
µg purified PG was incubated for 18 h with 0.1 M Tris-
acetate buffer, pH 7.3, in the presence of protease
inhibitors at 37ºC and in the presence (+) or absence
(-) of 2 mU chondroitinase ABC (Chase ABC). Intact PG
and Chase ABC digested core protein were subjected
to SDS-PAGE and stained with Coomassie blue (A), and
decorin antiserum after transferring to a nitrocellulose
membrane (B).
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DS chains. We identified and characterized
the small leucine-rich proteoglycan, deco-
rin, as one of the proteoglycans present in
Walker 256 carcinoma. Decorin was charac-
terized as a DS proteoglycan with three core
proteins (36, 46 and 56 kDa). The different
mRNA and/or core protein sizes generated
by alternative splicing have been described
for several proteoglycans, suggesting that
this phenomenon amounts to a functional
difference for the resulting proteoglycans:
aggrecan (25,26), versican/PG-M (27-29),
agrin (30), perlecan (31), and phosphacan
(32). As far as we know, there is no such
report related to decorin. When the decorin
gene was analyzed, two leader exons were
observed, which could be alternatively
spliced. However, this did not affect the
ultimate protein sequence since they were in
an untranslated region (33). Thus, different
core proteins found in decorin from Walker
256 carcinoma might be generated by in vivo
proteolysis or during the isolation and purifi-
cation process. It is well known that tumors
produce many proteinases responsible for
the degradation of matrix components,
thereby facilitating tumor invasion (34).
Decorin has been described as an anti-
tumoral molecule because of its ability to
modulate cell growth and of its effects on
several key elements including matrix as-
sembly, growth factor binding, and receptor
tyrosine kinase activity (6). Decorin may
interact with TGF-ß and with p21, both of
which are relevant to carcinogenesis and
tumor progression (35). Decorin binds to
TGF-ß and blocks TGF-ß-dependent growth
stimulation or cell inhibition, suggesting that
its mechanism of action is the neutralization
of TGF-ß activity (36). Decorin may directly
induce growth suppression by up-regulating
p21, a potent inhibitor of cyclin-dependent
kinases (37). Decorin binds to the epidermal
growth factor receptor, leading to activation
of the mitogen-activated protein kinase sig-
nal (38), with consequent mobilization of
intracellular calcium (39), and an increase in
endogenous p21 (32) resulting in ultimate
growth suppression (7,8). Decorin mRNA
and protein levels are markedly increased in
the peritumoral stroma of human colon can-
cers (10,40). This may represent a natural
biological response by the host connective
tissue cells to the invading neoplastic cells.
Decorin is one of the proteoglycans found in
Walker 256 rat mammary carcinoma, but
there are other proteoglycans containing sul-
fated glycosaminoglycan  (CS and HS), which
corresponds to about 50% of total sulfated
glycosaminoglycan.
Further studies are necessary to charac-
terize the other proteoglycans, which may
also play an important role in tumor growth
and progression, as demonstrated for decorin.
Figure 7. Amino acid sequences
of decorin core proteins of
Walker 256 tumor and compari-
son with other species. N-termi-
nal sequences: a, Walker 256
carcinoma; b, rat (19); c, mouse
(20); d, human (21); e, bovine
(22); f, rabbit (23); g, chicken
(24). The identical residues are
enclosed in boxes. *Indicates
the putative glycosaminoglycan
attachment site.
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